EP2285825A4 - Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor - Google Patents
Method of forming non-immunogenic hydrophobic protein nanoparticles and uses thereforInfo
- Publication number
- EP2285825A4 EP2285825A4 EP09743099A EP09743099A EP2285825A4 EP 2285825 A4 EP2285825 A4 EP 2285825A4 EP 09743099 A EP09743099 A EP 09743099A EP 09743099 A EP09743099 A EP 09743099A EP 2285825 A4 EP2285825 A4 EP 2285825A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- forming non
- uses therefor
- hydrophobic protein
- protein nanoparticles
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002209 hydrophobic effect Effects 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12713408P | 2008-05-09 | 2008-05-09 | |
PCT/US2009/002935 WO2009137112A1 (en) | 2008-05-09 | 2009-05-11 | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2285825A1 EP2285825A1 (en) | 2011-02-23 |
EP2285825A4 true EP2285825A4 (en) | 2012-11-28 |
EP2285825B1 EP2285825B1 (en) | 2020-07-15 |
Family
ID=41264904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09743099.5A Active EP2285825B1 (en) | 2008-05-09 | 2009-05-11 | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
Country Status (12)
Country | Link |
---|---|
US (2) | US8669225B2 (en) |
EP (1) | EP2285825B1 (en) |
JP (2) | JP5546532B2 (en) |
KR (1) | KR101616771B1 (en) |
CN (1) | CN102066399B (en) |
AU (1) | AU2009244742B2 (en) |
BR (1) | BRPI0908686B8 (en) |
CA (1) | CA2723563C (en) |
HK (1) | HK1158221A1 (en) |
IL (1) | IL209155A (en) |
RU (1) | RU2010146684A (en) |
WO (1) | WO2009137112A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170283T3 (en) | 2007-06-22 | 2019-04-15 | Univ Texas | CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING |
US20140234420A1 (en) * | 2008-05-09 | 2014-08-21 | Omathanu P. Perumal | Method of Treating Skin Disorders using Nanoscale Delivery Devices and Transdermal Enhancing Compositions |
US9233110B2 (en) | 2008-05-09 | 2016-01-12 | Omathanu P. Perumal | Protein nanocarriers for topical delivery |
CA2723563C (en) * | 2008-05-09 | 2017-12-12 | South Dakota State University | Method of forming non-immunogenic hydrophobic protein nanoparticles, and uses therefor |
US8697098B2 (en) | 2011-02-25 | 2014-04-15 | South Dakota State University | Polymer conjugated protein micelles |
US8779094B2 (en) | 2008-11-16 | 2014-07-15 | Board Of Regents, The University Of Texas System | Low viscosity highly concentrated suspensions |
BR112012033806B1 (en) | 2010-06-30 | 2019-10-15 | Unilever N.V. | COMPOSITION IN THE FORM OF PARTICULATE UNDERSTANDING HYDROPHobic POLYMER AND PHENOLIC COMPOUND, METHOD FOR PREPARING COMPOSITION AND USE OF COMPOSITION |
ES2724176T3 (en) * | 2010-07-16 | 2019-09-06 | Univ Navarra | Nanoparticles for encapsulation of compounds, their obtaining and uses |
CN102120823B (en) * | 2011-01-06 | 2016-08-03 | 鲁传华 | The synthesis of water solublity zein and the utilization in pharmaceutical preparation |
WO2012116272A2 (en) * | 2011-02-25 | 2012-08-30 | South Dakota State University | Polymer conjugated protein micelles |
CA2829629A1 (en) * | 2011-03-10 | 2012-09-13 | Board Of Regents, The University Of Texas System | Protein nanoparticle dispersions |
CA2883080A1 (en) * | 2011-08-26 | 2013-03-07 | Vecoy Nanomedicines Ltd. | Pathogen and substance traps |
EP2625966A1 (en) | 2012-02-13 | 2013-08-14 | Bionanoplus, S.L. | Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof |
US20150323530A1 (en) * | 2012-07-04 | 2015-11-12 | Empire Technology Development Llc | Quantum dot-protein complexes, films, and methods of use |
KR102045732B1 (en) * | 2012-12-28 | 2019-11-18 | 엘지디스플레이 주식회사 | Method Of Fabricating Water-Soluble Nano Particle Using Temperature-Sensitive Surfactan |
BR112015030525B1 (en) * | 2013-06-04 | 2023-01-24 | South Dakota State University | NANOPARTICLE |
IL228528A (en) | 2013-09-17 | 2015-01-29 | Technion Res & Dev Foundation | Potato protein nanoparticles |
US20170252446A1 (en) * | 2014-10-09 | 2017-09-07 | Andreas Voigt | Use of meso- and nanoporous material for surfactant trapping in nanoparticle suspensions |
WO2018071864A1 (en) | 2016-10-13 | 2018-04-19 | Thomas Jefferson University | Delivery compositions, and methods of making and using same |
US11318095B2 (en) * | 2017-06-02 | 2022-05-03 | Teika Pharmaceutical Co., Ltd. | Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same |
TWI642685B (en) * | 2017-07-26 | 2018-12-01 | 中原大學 | Novel peptide and application thereof |
CN109432433A (en) * | 2018-10-30 | 2019-03-08 | 中国药科大学 | A kind of preparation method and purposes of nano-carrier |
CN109730976B (en) * | 2018-12-24 | 2020-06-09 | 华中科技大学 | Method for preparing albumin nanoparticles based on free radical oxidation |
CN110251487B (en) * | 2019-08-01 | 2021-11-02 | 郑州大学 | Preparation method and application of alcohol soluble protein nanoparticles for improving drug-loading rate and oral bioavailability of docetaxel |
CN112121019B (en) * | 2020-09-23 | 2022-05-31 | 合肥工业大学 | Antioxidant starch-based dextrin composite nano-particles and preparation method and application thereof |
CN115025054B (en) * | 2022-06-09 | 2023-12-22 | 四川普锐特药业有限公司 | Preparation method of nano composition taking lactoferrin as carrier |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031231A1 (en) * | 1995-04-04 | 1996-10-10 | Elan Corporation, Plc | Controlled release biodegradable nanoparticles containing insulin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2236521A (en) | 1937-08-12 | 1941-04-01 | Zein Corp Of America | Ink |
US5330778A (en) | 1988-09-19 | 1994-07-19 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles |
EP0550436A1 (en) * | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
US5254673A (en) | 1991-12-26 | 1993-10-19 | Opta Food Ingredients, Inc. | Purification of zein from corn gluten meal |
MY153295A (en) * | 2004-09-29 | 2015-01-29 | Nestec Sa | Nanoparticulated whey proteins |
US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
EP2011472A4 (en) * | 2006-03-29 | 2013-01-23 | Fujifilm Corp | Casein nanoparticle |
WO2008013785A2 (en) * | 2006-07-24 | 2008-01-31 | Singh-Broemer And Company, Inc. | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
CN101485629B (en) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | Drug delivery system and preparation method thereof |
CA2723563C (en) * | 2008-05-09 | 2017-12-12 | South Dakota State University | Method of forming non-immunogenic hydrophobic protein nanoparticles, and uses therefor |
US9233110B2 (en) * | 2008-05-09 | 2016-01-12 | Omathanu P. Perumal | Protein nanocarriers for topical delivery |
-
2009
- 2009-05-11 CA CA2723563A patent/CA2723563C/en active Active
- 2009-05-11 WO PCT/US2009/002935 patent/WO2009137112A1/en active Application Filing
- 2009-05-11 RU RU2010146684/10A patent/RU2010146684A/en not_active Application Discontinuation
- 2009-05-11 CN CN200980123704.5A patent/CN102066399B/en active Active
- 2009-05-11 AU AU2009244742A patent/AU2009244742B2/en active Active
- 2009-05-11 EP EP09743099.5A patent/EP2285825B1/en active Active
- 2009-05-11 JP JP2011508521A patent/JP5546532B2/en active Active
- 2009-05-11 KR KR1020107027648A patent/KR101616771B1/en active IP Right Grant
- 2009-05-11 BR BRPI0908686A patent/BRPI0908686B8/en active IP Right Grant
- 2009-05-11 US US12/991,872 patent/US8669225B2/en active Active
-
2010
- 2010-11-04 IL IL209155A patent/IL209155A/en active IP Right Grant
-
2011
- 2011-11-18 HK HK11112508.7A patent/HK1158221A1/en unknown
-
2014
- 2014-03-10 US US14/203,476 patent/US9616021B2/en active Active
- 2014-05-13 JP JP2014099344A patent/JP5851550B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031231A1 (en) * | 1995-04-04 | 1996-10-10 | Elan Corporation, Plc | Controlled release biodegradable nanoparticles containing insulin |
Non-Patent Citations (3)
Title |
---|
C. DUCLAIROIR ET AL: "Formation of gliadin nanoparticles: Influence of the solubility parameter of the protein solvent", COLLOID AND POLYMER SCIENCE, vol. 276, no. 4, 7 May 1998 (1998-05-07), pages 321 - 327, XP055030929, ISSN: 0303-402X, DOI: 10.1007/s003960050246 * |
PARRIS-N ET AL: "Encapsulation of Essential Oils in Zein Nanospherical Particles", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, 15 June 2005 (2005-06-15), pages 4788 - 4792, XP002599360, ISSN: 0021-8561, [retrieved on 20050512], DOI: 10.1021/JF040492P * |
See also references of WO2009137112A1 * |
Also Published As
Publication number | Publication date |
---|---|
BRPI0908686B1 (en) | 2020-09-29 |
BRPI0908686B8 (en) | 2021-05-25 |
EP2285825B1 (en) | 2020-07-15 |
IL209155A0 (en) | 2011-01-31 |
JP5546532B2 (en) | 2014-07-09 |
US20110091565A1 (en) | 2011-04-21 |
KR101616771B1 (en) | 2016-04-29 |
HK1158221A1 (en) | 2012-07-13 |
RU2010146684A (en) | 2012-06-20 |
AU2009244742B2 (en) | 2014-11-06 |
CA2723563C (en) | 2017-12-12 |
US9616021B2 (en) | 2017-04-11 |
IL209155A (en) | 2016-07-31 |
AU2009244742A1 (en) | 2009-11-12 |
CN102066399B (en) | 2014-11-26 |
KR20110036704A (en) | 2011-04-08 |
US8669225B2 (en) | 2014-03-11 |
JP2014177474A (en) | 2014-09-25 |
EP2285825A1 (en) | 2011-02-23 |
JP5851550B2 (en) | 2016-02-03 |
JP2011519932A (en) | 2011-07-14 |
WO2009137112A1 (en) | 2009-11-12 |
CA2723563A1 (en) | 2009-11-12 |
CN102066399A (en) | 2011-05-18 |
US20140308351A1 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1158221A1 (en) | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor | |
EP2349918A4 (en) | Stable nanoparticles and methods of making and using such particles | |
IL248723A0 (en) | Bcr-complex-specific antibodies and methods of using same | |
IL225961A (en) | Liposomal nanoparticles and method of preparation thereof | |
EG27167A (en) | Microemulsifiers and methods of making and using same | |
EP2049291A4 (en) | Nanoparticle coatings and methods of making | |
EP2349237A4 (en) | Curcumin nanoparticles and methods of producing the same | |
EP2506967A4 (en) | Nanoparticle composition and methods of making the same | |
EP2451741A4 (en) | Semiconductor nanocrystal and preparation method thereof | |
EP2519664A4 (en) | Ligand-directed covalent modification of protein | |
EP2064153A4 (en) | Method of preparing cerium dioxide nanoparticles | |
EP2247305A4 (en) | Stabilized angiopoietin-2 antibodies and uses thereof | |
IL215765A0 (en) | Prion-free nanoparticle compositions and methods | |
AU2009234373A8 (en) | Coferons and methods of making and using them | |
EP2300549A4 (en) | Compositions and processes for producing durable hydrophobic and/or olephobic surfaces | |
GB0813381D0 (en) | An aerofoil and method of making an aerofoil | |
EP2059480A4 (en) | Methods of forming nanoparticles | |
EP2434536A4 (en) | Fine-processing agent and fine-processing method | |
HK1178917A1 (en) | Anti-bv8 antibodies and uses thereof bv8 | |
EP2328546A4 (en) | Aqueous cosmetic preparation and method for producing the same | |
IL197655A0 (en) | Emulsions and methods of their production | |
EP2250189A4 (en) | Glycopeptides and methods of making and using them | |
EP2284144A4 (en) | Polyfluoro-1-alkane and method of manufacture therefor | |
ZA201100019B (en) | Variant hhip1 protein and methods and uses thereof | |
EP3418307C0 (en) | Method of preparation of an aqueous dispersion of fructan-containing particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101130 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KAUSHIK, RADHEY, S. Inventor name: PODARALLA, SATHEESH, K. Inventor name: PERUMAL, OMATHANU, P. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KAUSHIK, RADHEY, S. Inventor name: PODARALLA, SATHEESH, K. Inventor name: PERUMAL, OMATHANU, P. |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20121031 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B82B 3/00 20060101ALI20121025BHEP Ipc: A61K 38/00 20060101ALI20121025BHEP Ipc: C07K 1/02 20060101ALI20121025BHEP Ipc: C07K 1/14 20060101AFI20121025BHEP |
|
17Q | First examination report despatched |
Effective date: 20160719 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602009062414 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07K0001140000 Ipc: A61K0047690000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/69 20170101AFI20200206BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200217 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009062414 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1290244 Country of ref document: AT Kind code of ref document: T Effective date: 20200815 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1290244 Country of ref document: AT Kind code of ref document: T Effective date: 20200715 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201016 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201015 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201015 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201116 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201115 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009062414 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210416 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210511 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210511 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090511 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230517 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230522 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230721 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |